Compared to TAVR(TAVI) and Prosthetics valves, AVNeo has various advantages. Though the lifespan of this procedure needs to be further assessed, AVNeo can provide various contribution to patients that need only a shorter time of durability. By using the patient’s own tissue, the valve is able to mimic the natural movement of a healthy aortic valve. See below for highlighted benefits of AVNeo.


AVNeo is as invasive as other procedures, but is more invasive than the transcatheter aortic valve replacement (TAVR).

Proven Mid Term Durability

Durability has been proven for 12 years at this moment and is still ongoing.

Anti Coagulation Drugs Not Needed

Anti-coagulation drugs are often associated with major disadvantages. These often reduce the Quality of Life (QOL) for the patient. As AVNeo does not require anti-coagulation drugs, it is advantageous over tissue heart valves and mechanical valves.

Wide Target Age

The target age for AVNeo procedures ranges from pediatric patients to elderly patients. There have been reports showing that AVNeo has been implemented on patients from under 1 year old to 90 years old.

Lower Cost for Patient and Health Care System

By using the patients own pericardium (heart membrane), the cost is substantially lowered compared to TAVR(TAVI) or other prosthetic valves.